Skip to content
Triangle logo TriangleGet started
← Langerhans Cell Histiocytosis

HEALTH PROFESSIONAL · SOURCE READING

Bisphosphonate therapy

Source: Langerhans Cell Histiocytosis Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: January 6, 2025 · Captured 2026-09-09.

Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.

Context: Childhood LCH / Recurrent, Refractory, or Progressive Childhood LCH / Treatment of recurrent, refractory, or progressive low-risk disease: single-system or multisystem LCH

Bisphosphonate therapy is also effective for treating patients with recurrent LCH bone lesions.[142]

Source links and citations

Evidence (bisphosphonate therapy):

In a survey from Japan, 16 patients with bone lesions were treated with bisphosphonate therapy. None of the patients had risk-organ disease. Most patients received six cycles of pamidronate at 1 mg/kg per course, given at 4-week intervals.[110][Level of evidence C3]

Source links and citations

In a survey from Japan, 16 patients with bone lesions were treated with bisphosphonate therapy. None of the patients had risk-organ disease. Most patients received six cycles of pamidronate at 1 mg/kg per course, given at 4-week intervals.[110][Level of evidence C3]

Of the 16 patients, 12 were successfully treated.

In a survey from Japan, 16 patients with bone lesions were treated with bisphosphonate therapy. None of the patients had risk-organ disease. Most patients received six cycles of pamidronate at 1 mg/kg per course, given at 4-week intervals.[110][Level of evidence C3]

Skin and soft tissue LCH lesions also resolved in the responding patients.

In a survey from Japan, 16 patients with bone lesions were treated with bisphosphonate therapy. None of the patients had risk-organ disease. Most patients received six cycles of pamidronate at 1 mg/kg per course, given at 4-week intervals.[110][Level of evidence C3]

Eight of the 12 patients remained disease free at a median of 3.3 years.

Other bisphosphonates, such as zoledronate and oral alendronate, have also been successful in treating bone LCH.[111-113][Level of evidence C3]

Source links and citations

Publication references

Read the original reference and check its publication notices.

Preserved source evidence · Not medical advice